BioNTech SE

BioNTech SE is a next-generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, bispecific checkpoint immunomodulators, targeted cancer antibodies, and small molecules. BioNTech is globally recognized for its role in developing the first authorized mRNA-based vaccine, Comirnaty, in partnership with Pfizer. Post-pandemic, the company has strategically shifted its focus toward becoming a multi-product oncology powerhouse, leveraging its strong cash position to acquire AI specialist InstaDeep and mRNA pioneer CureVac. The company is heavily invested in 'AI-first' drug discovery, utilizing its Kyber supercomputer and DeepChain multiomics platform to accelerate R&D.